<DOC>
	<DOCNO>NCT00621322</DOCNO>
	<brief_summary>This observer blind study assess safety immunogenicity different formulation GSK Biologicals ' 692342 tuberculosis vaccine healthy adult age 18 45 year positive PPD skin test . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Safety Immunogenicity Study GSK Biologicals Tuberculosis Vaccines ( 692342 ) Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . A male female , include , 18 45 year age time first vaccination . Written inform consent obtain subject prior study procedure . Free obvious health problem establish medical history clinical examination enrolment study . If subject female , must nonchildbearing potential childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution 2 month completion vaccination series . No evidence pulmonary pathology confirm chest Xray . No history extrapulmonary TB . Clinically normal laboratory value creatinine , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , complete blood count ( CBC ) urinalysis . Seronegative human immunodeficiency virus1 2 ( HIV1 2 ) antibody . Subjects must PPD positive skin reactivity 48 72 hour PPD skin test administration . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Any chronic drug therapy continue study period , exception vitamin and/or dietary supplement , herbal medication , birth control pill , antihistamine seasonal allergy SSRIs . History previous administration experimental Mycobacterium tuberculosis vaccine . History previous exposure experimental product contain MPL QS21 . Administration immunoglobulins , immunotherapy and/or blood product within three month precede first dose study vaccination , plan administration study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Any confirm suspect immunosuppressive immunodeficient condition base medical history physical examination . A family history ( first generation ) congenital hereditary immunodeficiency . History acute chronic illness medication , opinion investigator , may interfere evaluation safety immunogenicity vaccine . History neurological disorder seizure . History allergic reaction anaphylaxis previous immunisation . History allergic disease reaction likely exacerbate component vaccine . History chronic alcohol consumption and/or drug abuse . Major congenital defect . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Tuberculosis vaccine</keyword>
</DOC>